Results 81 to 90 of about 1,066 (137)
Some of the next articles are maybe not open access.

Related searches:

Abstracts of the 2022 SPP Spring Meeting

Pediatric and Developmental Pathology, 2022
Background: The implementation of next-generation sequencing in combination with sensitive software tools for cancer diagnosis has markedly increased the ability to detect genetic abnormalities. Such assays have resulted in accurate diagnoses and allowed
Nos   +10 more
semanticscholar   +1 more source

2022 Annual Meeting of The North American Menopause Society October 12 - 15, 2022, Atlanta, GA.

Menopause, 2022
Objective: Hot flashes are a common side effect of endocrine therapy (ET) in breast cancer survivors. Hot flashes are associated with poor quality of life and treatment nonadherence. The Embr Wave is a noninvasive wearable device that applies cooling and
A. Vetter   +14 more
semanticscholar   +1 more source

2022 CCCC Chair’s Letter

College Composition & Communication, 2022
Hassel officially started his service as an elected CCCC officer on Dec 23, 2019, but for four years prior to that, he was an ex officio member of the CCCC Executive Committee (EC) by virtue of his role as editor of Teaching English in the Two-Year ...
Holly Hassel
semanticscholar   +1 more source

Performance Analysis of 81.6 kWp Roof-top Solar PV Installed on Canopy Structure at WRLDC, Mumbai

National Power Systems Conference, 2022
Government of India has set the target of 175GW of Renewable Energy (RE) Capacity by Dec 2022 [1]. This will have impact on generation from fossil fuel in India and reduce the carbon footprint.
Pramod Kumar Prajapati   +6 more
semanticscholar   +1 more source

Making Structural Discrimination Visible: A Call for Intersectional Bioethics

American Journal of Bioethics, 2022
cause of death 1999–2019. Accessed Dec 30, 2021. http:// wonder.cdc.gov/ucd-icd10.html. COVID Tracking Project. n.d. Racial data dashboard. Accessed Dec 30, 2021. https://covidtracking.com/race/ dashboard Hambright, T. Z. 1969.
Lisa Brünig, Sabine Salloch
semanticscholar   +1 more source

Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation

Cancer Research, 2022
Background: KRASG12C mutation acts as an oncogenic driver and occurs in ~15% of NSCLC. D-1553 is a novel and potent small molecule inhibitor of KRASG12C. Here we present the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of D-1553
H. Jian   +16 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy